Table 1.
Characteristics of 32 CML patients according to treatment-free remission (TFR) or molecular relapse after imatinib discontinuation
| Patients in TFR no. 19 (59 %) | Relapsed patients no. 13 (41 %) | p | |||
|---|---|---|---|---|---|
| Age at diagnosis (mean, range) | 74 (47–88) | 56 (37–77) | 0.004 | ||
| Leukocytes at diagnosis ×103/uL (mean, range) | 50.47 (8.15–221) | 69 (19.8–263) | ns | ||
| Platelets at diagnosis ×103/uL (mean, range) | 472 (178–918) | 357 (171–695) | ns | ||
| Months to CMR (median, range) | 28 (3–88) | 30 (6–93) | ns | ||
| Months of TKIs (median, range) | 86 (24–127) | 84 (45–143) | ns | ||
| Months of TKIs >60 (no., %) | 13 | 68.4 | 12 | 92.3 | ns |
| Male gender (no., %) | 16 | 84.2 | 8 | 61.5 | ns |
| Sokal risk (no., %) | |||||
| Low | 6 | 31.6 | 8 | 61.5 | ns |
| Intermediate | 10 | 52.6 | 3 | 23.1 | ns |
| High | 3 | 15.8 | 2 | 15.4 | ns |
| First-line TKI treatment (no., %) | 11 | 57.9 | 11 | 84.6 | ns |
| Previous IFN treatment (no., %) | 8 | 42.1 | 2 | 15.4 | ns |
| Imatinib first-line TKI treatment (no., %) | 19 | 100 | 13 | 100 | ns |
| Nilotinib second-line TKI treatment (no., %) | 1 | 5.3 | 1 | 7.7 | ns |
| Age-corrected relative telomere length (mean ± SD) | 0.01 ± 0.14 | 0.20 ± 0.21 | 0.01 |
pres present, CMR complete molecular response, TKIs tyrosine kinase inhibitors, IFN interferon, ns not significant, SD standard deviation